Investigational new drug-directed, 5-Day repeat dose toxicity study of 4-[3-(2-Nitro-1-Imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol® in sprague-dawley rats

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 6, 2010, Pages 497-504

  Papadopoulou, Maria V ^a   Bloomer, William D ^a   Torti, Vincent R ^b   Page, John G ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; NEW DRUG; NSC 709257; PACLITAXEL; UNCLASSIFIED DRUG; 4-(3-(2-NITRO-1-IMIDAZOLYL)-PROPYLAMINO)-7-CHLOROQUINOLINE HYDROCHLORIDE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; AUTOPSY; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; MALE; MONOCYTE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOCYTE COUNT; ANIMAL; DRUG ADMINISTRATION; DRUG SURVEILLANCE PROGRAM; INTRAVENOUS DRUG ADMINISTRATION; SEX DIFFERENCE; SPRAGUE DAWLEY RAT; TIME; TOXICITY;

ANIMALIA; RATTUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEMALE; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PACLITAXEL; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; TIME FACTORS;

EID: 77952253835     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00530.x     Document Type: Article

References (32)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Nat Cancer Inst 2001 93 : 266 276. (Review)
2. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007 19 : 427 442.
3. Lee D-J, Trotti A, Spencer S, Rostock R, Fischer C, von Roemeling R et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int J Radiat Oncol Biol Phys 1998 42 : 811 815.
4. Gatineau M, Rixe O, Chevalier TL. Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study. Clin Lung Cancer 2005 6 : 293 298.
5. Smith HO, Jiang CS, Weiss GR, Hallum AV 3rd., Liu PY, Robinson WR 3rd. et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 2006 16 : 298 305.
6. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 2001 85 : 625 629.
7. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000 82 : 1984 1990.
8. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M et al. A Phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 2008 14 : 7110 7115.
9. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007 13 : 3922 3932.
10. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)- propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 2000 12 : 185 192.
11. Wilson WR, Denny WA. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In : Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF (eds). Radiation Research, A Twentieth-Century Perspective, Vol. 2. Academic Press
12. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 2003 9 : 5714 5720. (Review)
13. Papadopoulou MV, Bloomer WD. Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs. Drugs Future 2004 29 : 807 819.
14. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)- propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol Res 2000 12 : 325 333.
15. Papadopoulou MV, Bloomer WD, Hollingshead MG. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts. Anticancer Res 2005 25 : 1865 1870.
16. Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG. Advantage in combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts. Radiation Res 2007 168 : 65 71.
17. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou M et al. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 2001 94 : 564 571.
18. Papadopoulou MV, Telfer B, Shannon A, Babur M, Bloomer W, Stratford I et al. NLCQ-1 [NSC 709257] controls metastatic disease when administered post radiotherapy. Proc Am Assoc Cancer Res Annu Meet 2007 48 : 2409.
19. Papadopoulou MV, Ji M, Bloomer WD. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 1998 42 : 775 779.
20. Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 2001 48 : 160 168.
21. Papadopoulou MV, Ji M, Ji X, Bloomer WD. Therapeutic advantage from combining 5-fluororouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo. Comparison with tirapazamine. Cancer Chem Pharmacol 2002 50 : 291 298.
22. Papadopoulou MV, Ji M, Ji X, Bloomer WD. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo. Comparison with tirapazamine. Oncol Res 2002 13 : 47 54.
23. Papadopoulou MV, Ji X, Bloomer WD. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo. J Exp Ther Oncol 2006 5 : 261 272.
24. Papadopoulou MV, Ji X, Bloomer WD. Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice. Proc Am Assoc Cancer Res Annu Meet 2002 43 : 1092.
25. Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG. Therapeutic advantage from combining Paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem Pharmacol 2002 50 : 501 508.
26. Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J Exp Ther Oncol 2002 2 (5 298 305.
27. Page JG, Torti VR. Single Dose Range-Finding Intravenous Toxicity Study of NLCQ-1 (NSC-709257) in Sprague-Dawley Rats. Report submitted to Evanston Northwestern Healthcare by Southern Research Institute
28. Papadopoulou MV, Bloomer WD, Torti VR, Page JG. Pilot, five-day repeat dose toxicity study of NLCQ-1 (NSC 709257) in Sprague-Dawley rats. Molecular targets and cancer therapeutics: discovery, biology and clinical applications. November 17-21, 2003, Boston, Massachusetts. Clin Cancer Res 2003 9 : 6084S, Part 2 Suppl.
29. National Research Council. Institute of Laboratory Animal Resources, Commission on Life Sciences. Guide for the Care and Use of Laboratory Animals. National Academy Press
30. Tomigahara Y, Onogi M, Saito K, Isobe N, Kaneko H, Nakatsuka I. Metabolism of cyanox in rat. II. Sex-related differences in oxidative dearylation and disulphuration. Xenobiotica 2000 30 : 395 406.
31. Reid JM, Squillace DP, Ames MM. Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chemother Pharmacol 2003 51 : 483 487.
32. Papadopoulou MV, Bloomer WD, Torti VR, Page JG. IND-Directed toxicology and pharmacokinetic study of NLCQ-1 (NSC 709257) in Beagle dogs. Basic Clin Pharmacol Toxicol 2010 106 : 511 522.